PBRM1: Potential Biomarker for Tumor Targeted Therapy and Immune Checkpoint Therapy

PBRM1 appears as a tumor suppressor gene in a variety of tumors. The value of PBRM1 mutation or expression is different for the prognosis prediction of different kinds of tumors. Studies have revealed that JAK/STAT3, PBRM1/RLR and other signals were participated in the process of PBRM1 activating immune system, inflammatory responses and the transform of inflammation to cancer. This process modified the sensitivity of the patients to biological targeted therapy and immune checkpoint therapy. The combination of immune checkpoint inhibitor and targeted drug is the develop trends of cancer therapy in the future. In this review, we discuss the role of PBRM1 in the prognosis guidance of patients with different tumors, and explain the importance of PBRM1 detection in guiding the selection of drugs and treatment strategies and evaluating the efficacy.